Products for Research Use Only

Rifaximin

CAT: 0804-HY-13234-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13234-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL) [1][2].
CAS Number
80621-81-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Bacterial; DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/Rifaximin.html
Purity
99.64
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C1C2=C(O[C@@]1(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H](O)[C@@H](C)/C=C/C=C(C)\C3=O)C)O)C)OC(C)=O)C)OC)C)C(C)=C(O)C4=C2C5=C(C(N3)=C4O)N6C(C=C(C)C=C6)=N5
Molecular Formula
C43H51N3O11
Molecular Weight
785.88
Precautions
H302, H315, H319, H335
References & Citations
[1]Veronica Ojetti, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5 (6) :675-82.|[2]Giuseppe Esposito, et al. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol. 2016 Aug;49 (2) :639-45.|[3]Stefano Fiorucci, et al.Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66 (4) :246-56.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
020670Rifaximin